Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Lymphoma, T-Cell, Peripheral 3Myelodysplastic Syndromes 2Lymphoma, T-Cell 2Leukemia, Myeloid, Acute 2Uveal Melanoma 1Neuroendocrine Tumors 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1Eye Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Neuroendocrine 1Blast Crisis 1

Interventions

Nivolumab 6atezolizumab 5Cisplatin 5Ipilimumab 4Carboplatin 4Etoposide 3pembrolizumab 2gallium Ga 68 dotatate 2dostarlimab 2Temozolomide 2Positron Emission Tomography Computed Tomography 2Paclitaxel 2Magnetic Resonance Imaging 2Irinotecan 2Immunoglobulin G 2IFL protocol 2Disulfides 2zimberelimab 1tivozanib 1repotrectinib 1niraparib 1lutetium Lu 177 dotatate 1lenvatinib 1iadademstat 1durvalumab 1cabozantinib 1budigalimab 1belinostat 1Topotecan 1Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Neuroendocrine × belinostat × 1 year × Clear all
NCT06406465 2026-06-05

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
60 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡